Cancer detection tech uses AI, whole-genome sequencing An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.
Cancer intelligence company recently received $100m in funding to help accelerate the development and commercialization of its Intelligence Platform. The cancer diagnostics technology uses artificial intelligence (AI) pattern recognition paired with whole-genome analysis to achieve rapid, accurate detection of residual disease; according to the company, the technology is up to 100 times more sensitive than similar technologies.
Asaf Zviran, co-founder and CEO of C2i Genomics, spoke with Outsourcing-Pharma about the technology, plans for the future, and how his experience as a cancer survivor helped inform its development.